<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04398173</url>
  </required_header>
  <id_info>
    <org_study_id>ProBiopsy-RM19</org_study_id>
    <nct_id>NCT04398173</nct_id>
  </id_info>
  <brief_title>Detection Rate of Prostate Cancer in Men Undergoing MRI</brief_title>
  <official_title>A Retrospective Observational Study to Assess Prostate Cancer Detection Rate in Men Undergoing Magnetic Resonance Imaging: Comparison Between Subjects With Previous Negative Biopsy and Biopsy Naive Men</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fondazione del Piemonte per l'Oncologia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fondazione del Piemonte per l'Oncologia</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess prostate cancer (PCa) detection rate in men undergoing magnetic resonance imaging
      (MRI) before planning prostate biopsy. Results will be stratified considering men
      with/without previous negative prostate biopsy.

      Secondary objective will be to compute the negative predictive value of MRI in subject with
      no lesion detected at imaging or no cancer confirmed at biopsy, considering a follow-up of at
      least 2 years.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The trial is a retrospective observational study, with the aim to compare two cohorts of
      patients with suspicion of PCa who will undergo MRI. Group A is composed by patients with
      previous negative biopsy, while group B is composed by men with no previous negative prostate
      biopsy.

      To reach primary aim, men with positive MRI (clinically significant lesions with PI-RADS
      score &gt;= 3) and biopsy data will be considered.

      In men with negative MRI (clinically insignificant lesions or regions classified as PI-RADS 2
      at MRI), follow-up with PSA data and repeated MRI and/or biopsy will be considered.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">November 1, 2014</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">October 31, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>PCa detection rate</measure>
    <time_frame>24 months</time_frame>
    <description>Number of men with positive prostate biopsy over the number of men with a positive MRI</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Negative predictive value of MRI</measure>
    <time_frame>24 months</time_frame>
    <description>Number of men with negative MRI or positive MRI but negative biopsy who are confirmed as negative for PCa during the follow-up over the total number of subjects considered during the follow-up</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">400</enrollment>
  <condition>Prostatic Neoplasm</condition>
  <arm_group>
    <arm_group_label>Group A (previous negative biopsy)</arm_group_label>
    <description>Men with clinical suspicion of PCa, previous negative prostate biopsy who underwent prostate MRI</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B (biopsy naive)</arm_group_label>
    <description>Men with clinical suspicion of PCa, no previous negative prostate biopsy who underwent prostate MRI</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>multiparametric MRI</intervention_name>
    <description>T1-w, T2-w, diffusion weighted and dynamic contrast-enhanced imaging</description>
    <arm_group_label>Group A (previous negative biopsy)</arm_group_label>
    <arm_group_label>Group B (biopsy naive)</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Men with clinical suspicion of PCa, eligible for prostate biopsy
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age 50 and life expectancy greater than 10 years

          -  PSA values persistently greater than 4 ng/ml

          -  multiparametric MRI of the prostate between nov-2014 and nov-2016

          -  MRI with endorectal coil

        Exclusion Criteria:

          -  previous history of PCa
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Fondazione del Piemonte per l'Oncologia - Candiolo Cancer Institute</name>
      <address>
        <city>Candiolo</city>
        <state>Turin</state>
        <zip>10060</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>January 30, 2020</study_first_submitted>
  <study_first_submitted_qc>May 18, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 21, 2020</study_first_posted>
  <last_update_submitted>May 21, 2020</last_update_submitted>
  <last_update_submitted_qc>May 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 26, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>magnetic resonance imaging</keyword>
  <keyword>prostate biopsy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

